查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853959

牛結核病診斷市場按檢測類型、產品和最終用戶分類 - 全球預測 2025-2032

Bovine Tuberculosis Diagnosis Market by Test Type, Product, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，牛結核病診斷市場將成長至 16.4816 億美元，複合年成長率為 8.03%。

關鍵市場統計數據
基準年 2024 8.8785億美元
預計年份：2025年 9.608億美元
預測年份 2032 16.4816億美元
複合年成長率 (%) 8.03%

本書對影響全球牛結核病診斷決策的科學、操作和政策因素進行了簡明扼要而又權威的概述。

牛結核病仍然是動物健康領域的持續挑戰，對畜牧業生產力、貿易誠信和公共衛生都造成了重大影響。牛病菌感染的診斷需要免疫學和分子生物學平台的精確性，實驗室在實施篩檢和確診流程時必須權衡靈敏度、特異性和可操作性。診斷策略是監測計畫、監管決策和市場准入通訊協定的基礎，凸顯了穩健且可互通的偵測框架的重要性。

近年來，技術成熟度和營運壓力相互交織，重塑了相關人員評估診斷效能的方式。免疫測量、核酸擴增技術和實驗室自動化的進步正在改變檢測模式，而政策變化和供應鏈波動迫使實驗室和採購團隊重新評估供應商關係和緊急計畫。因此，決策者需要平衡且基於證據的見解，以協調監管合規、畜群健康目標、成本效益高的實驗室運作和診斷技術的推廣應用。

本執行摘要總結了現代診斷技術的動態發展，探討了監管和貿易環境的影響，並提供了基於細分市場的洞察，以指導採購、實驗室部署和研究優先順序的確定。它著重於可操作的分析，旨在支援在各種檢測方式和終端用戶環境中做出快速且合理的選擇，並清晰地展現區域營運差異和策略供應商考量。

技術進步、綜合監測框架和採購韌性如何從根本上重塑全球牛結核病診斷生態系統

技術創新、跨部門合作以及對綜合監測的重新重視正在變革時期牛結核病的診斷格局。改進的免疫檢測，包括更具選擇性的抗原和多重檢測平台，在不犧牲靈敏度的前提下提高了特異性，並減少了已接種疫苗和交叉反應人群中的假陽性結果。同時，核酸擴增方法變得更加便捷快速，使得確診檢測能夠縮短週轉時間，並提高了菌株層級流行病學的可追溯性。

在營運方面，實驗室正在採用數位化工作流程和自動化技術來提高檢測效率，同時保持品管。現場採樣、實驗室資訊管理系統和國家監測資料庫之間的互聯互通，提高了即時情境察覺，並有助於開展有針對性的干涉措施。此外，「同一健康」理念正在加強獸醫服務、公共衛生部門和環境機構之間的合作，鼓勵跨部門資料共用和診斷標準的統一。

隨著相關人員將韌性置於優先地位，市場動態也在改變。籌資策略日益強調供應商多元化、有效的第二供應商以及庫存管理，以降低中斷風險。不斷變化的監管預期強化了這一轉變，這些預期要求為新型檢測方法提供更清晰的認證途徑，並簡化檢驗通訊協定以加快部署。總而言之，這些趨勢正在加速診斷生態系統的現代化，並影響實驗室、監管機構和產業合作夥伴的優先事項。

了解美國關稅措施（截至 2025 年）對診斷試劑供應的多方面影響，包括供應鏈、採購和驗證等方面。

2025年美國關稅的累積影響為診斷供應鏈、採購計畫和競爭定位帶來了新的考量。關稅主導的成本壓力直接影響進口診斷設備和關鍵試劑，進而影響採購時機、庫存策略以及國內生產和區域採購的相對吸引力。實驗室和政府採購負責人在選擇常規檢測和確診檢測平台時，正在重新評估總到岸成本和物流前置作業時間。

除了對單價的影響外，關稅還促使供應商和買家進行策略調整。先前將生產集中在單一地區的供應商正在加速近岸外包和多元化佈局，以維持市場准入並保護其利潤結構。這種轉變影響了產品供應計劃、售後服務支援模式和驗證週期。因此，診斷公司在選擇平台時，不僅要考慮價格波動，還要考慮服務的連續性和驗證成本。

對於公共衛生和獸醫部門而言，關稅凸顯了聯合採購框架、集中採購和官民合作關係的重要性，這些機制能夠利用規模效應來吸收貿易相關的成本衝擊。同時，研發重點也在轉變。為了在進口中斷的情況下維持檢測能力，對替代試劑、檢測方法再製造以及現有平台互通性的投資正被優先考慮。這些動態的累積效應凸顯了積極主動的供應鏈風險管理和協調一致的政策因應措施對於保障診斷準備工作的必要性。

基於全面細分的診斷洞察揭示了不同測試方式、產品系列和最終用戶業務優先順序之間的獨特需求。

細緻的市場區隔視角有助於明確如何根據偵測類型、產品類型和終端使用者環境調整診斷策略。基於檢測類型的市場分析區分了免疫學篩檢（例如牛結核病檢測、比較性單次皮內子宮頸檢測）、血清學檢測（例如酶聯免疫吸附試驗 (ELISA)）、細胞反應檢測（例如γ干擾素檢測）以及透過聚合酶鍊式反應 (PCR) 進行的分子確認。皮內檢測因其操作簡便，仍然是現場篩檢的首選；基於ELISA的檢測可提供可擴展的血清學監測；γ干擾素檢測能夠實現早期檢測，這可能透過細胞介導的免疫對抗措施實現；而PCR則可以進行病原體層面的確認和菌株鑑定。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 以 CRISPR-Cas12a橫向流動化驗對高密度牛中的牛結核病抗原進行超靈敏檢測
  • 將智慧型手機紅外線熱成像技術與機器學習模型結合，用於酪農牛潛伏性結核病的早期篩檢。
  • 開發用於按需同時檢測牛結核病和其他呼吸道病原體的連接複用微流體實驗室晶片平台
  • 引入攜帶式即時PCR診斷方法，用於在偏遠牲畜交易站快速確診牛結核病
  • 部署奈米抗體功能化的電化學生物感測器以提高牛結核病抗體監測計畫的特異性和靈敏度
  • 新型γ干擾素釋放試驗的監管核准趨勢及其對國家牛結核病根除策略的影響

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章牛結核病診斷市場（依檢測類型分類）

  • 牛結核病檢測
    • 比較性皮內子宮頸試驗
    • 單次皮內子宮頸試驗
  • ELISA
  • γ干擾素檢測
  • PCR

第9章牛結核病診斷產品市場

  • 裝置
    • ELISA 閱讀器
    • PCR儀
  • 套件
    • 牛結核病檢測套組
    • ELISA試劑套件
    • γ干擾素干擾素試劑套件
    • PCR試劑套件
  • 試劑
    • 抗原
    • 酵素
    • 引子和探針
      • 底漆
      • 探測

第10章牛結核病診斷市場（以最終用戶分類）

  • 診斷實驗室
  • 政府機構
  • 研究所
  • 獸醫診所

第11章牛結核病診斷市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章牛結核病診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 各國牛結核病診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Zoetis Inc.
    • IDEXX Laboratories, Inc.
    • Bio-Rad Laboratories, Inc.
    • Merck & Co., Inc.
    • Neogen Corporation
    • HIPRA SA
    • Elanco Animal Health Incorporated
    • Biogal-Galed Laboratories Ltd.
    • VMRD, Inc.
Product Code: MRR-0D217D5AD942

The Bovine Tuberculosis Diagnosis Market is projected to grow by USD 1,648.16 million at a CAGR of 8.03% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 887.85 million
Estimated Year [2025] USD 960.80 million
Forecast Year [2032] USD 1,648.16 million
CAGR (%) 8.03%

A concise yet authoritative orientation to the evolving scientific, operational, and policy drivers shaping bovine tuberculosis diagnostic decision-making globally

Bovine tuberculosis remains a persistent animal health challenge with significant implications for livestock productivity, trade integrity, and public health interfaces. The diagnosis of Mycobacterium bovis infections demands precision across a range of immunological and molecular platforms, and laboratories must balance sensitivity, specificity, and operational feasibility when implementing screening and confirmatory workflows. Diagnostic strategies underpin surveillance programs, regulatory decisions, and market access protocols, which elevates the importance of robust, interoperable testing frameworks.

Recent years have seen a convergence of technological maturation and operational pressures that reshape how stakeholders evaluate diagnostic performance. Advances in immunoassays, nucleic acid amplification techniques, and laboratory automation have altered testing paradigms, while policy shifts and supply chain volatility force laboratories and procurement teams to reassess vendor relationships and contingency plans. As a result, decision-makers require balanced, evidence-based insights to align diagnostic adoption with regulatory compliance, herd health objectives, and cost-effective laboratory operations.

This executive summary synthesizes contemporary diagnostic dynamics, examines the regulatory and trade environment influences, and offers segmentation-based insights to inform procurement, laboratory deployment, and research prioritization. The emphasis is on actionable analysis that supports rapid, defensible choices across testing modalities and end-user settings, while maintaining a clear view of regional operational heterogeneity and strategic vendor considerations.

How technological advances, integrated surveillance frameworks, and procurement resilience are fundamentally reshaping bovine tuberculosis diagnostic ecosystems worldwide

Diagnostic landscapes for bovine tuberculosis are undergoing transformative shifts driven by technological innovation, cross-sector collaboration, and a renewed focus on integrated surveillance. Immunoassay refinements such as more selective antigens and multiplexed platforms are improving specificity without sacrificing sensitivity, thereby reducing false positives in vaccinated or cross-reactive populations. In parallel, nucleic acid amplification methods have become more accessible and faster, enabling confirmatory testing with reduced turnaround times and enhanced traceability of strain-level epidemiology.

Operationally, laboratories are embracing digital workflows and automation to scale throughput while preserving quality control. Connectivity between field sampling, laboratory information management systems, and national surveillance databases is improving real-time situational awareness and facilitating targeted interventions. Moreover, the One Health paradigm is strengthening collaborative ties between veterinary services, public health authorities, and environmental agencies, prompting cross-disciplinary data sharing and harmonized diagnostic standards.

Market dynamics are also shifting as stakeholders prioritize resilience. Procurement strategies increasingly emphasize supplier diversification, validated secondary sourcing, and inventory management to mitigate disruption risks. These shifts are reinforced by evolving regulatory expectations that require clearer evidentiary pathways for novel assays and streamlined validation protocols for emergency deployment. Taken together, these trends are accelerating the modernization of diagnostic ecosystems and shaping the priorities of laboratories, regulators, and industry partners.

Understanding the multifaceted supply chain, procurement, and validation consequences arising from United States tariff actions enacted during 2025 that affect diagnostic availability

The cumulative effects of United States tariff measures implemented in 2025 have introduced new considerations across diagnostic supply chains, procurement planning, and competitive positioning. Tariff-driven cost pressures have a direct impact on imported diagnostic instruments and critical reagents, which in turn influence procurement timing, inventory strategies, and the relative attractiveness of domestic manufacturing or regional sourcing. Laboratories and government purchasers are reassessing total landed costs and logistical lead times when selecting platforms for routine and confirmatory testing.

Beyond unit cost impacts, tariffs have catalyzed strategic shifts among suppliers and buyers. Vendors that previously concentrated manufacturing in single geographies are accelerating nearshoring and diversification initiatives to preserve market access and protect margin structures. This reorientation has implications for product availability timelines, after-sales support models, and validation cycles, since newly localized production lines often require regulatory re-submissions or additional quality audits. Consequently, diagnostic adopters must factor in not only price variance but also service continuity and validation overheads when selecting platforms.

For public health and veterinary authorities, tariffs have emphasized the importance of collaborative procurement frameworks, pooled purchasing, and public-private partnerships that can leverage scale to absorb trade-related cost shocks. At the same time, research and development priorities are adapting: investments in reagent substitutes, assay reformulation, and interoperability of legacy platforms are being prioritized to maintain testing capacity under disrupted import conditions. These cumulative dynamics underscore the need for proactive supply chain risk management and collaborative policy responses to safeguard diagnostic readiness.

Comprehensive segmentation-driven diagnostic insights that reveal distinct requirements across test modalities, product families, and diverse end-user operational priorities

A nuanced segmentation lens clarifies how diagnostic strategies must be tailored across test types, product categories, and end-user settings. Based on Test Type, market analysis differentiates between immunological screening such as Caudal Fold Test modalities with their Comparative Intradermal Cervical and Single Intradermal Cervical variants, serological assays like ELISA, cellular response measures exemplified by Gamma Interferon Assay, and molecular confirmation via PCR. Each test category offers a distinct mix of diagnostic attributes: the intradermal tests remain frontline for field screening with operational simplicity, ELISA-based tests provide scalable serological surveillance, Gamma Interferon assays deliver earlier detection in some cases through cell-mediated immunity measures, and PCR affords pathogen-level confirmation and strain characterization.

Based on Product, diagnostic ecosystems encompass Instruments, Kits, and Reagents that together form end-to-end testing workflows. Instruments range from ELISA readers to PCR machines, whose throughput, automation, and data integration capabilities influence laboratory efficiency and cost per test. Kits include tailored solutions for Caudal Fold Test Kits, ELISA Kits, Gamma Interferon Assay Kits, and PCR Kits, each requiring validation for specific host populations and use-cases. Reagents cover Antigens, Enzymes, and Primers and Probes, with primers and probes further disaggregated into primer and probe components critical for molecular specificity. Quality, cold-chain robustness, and batch-to-batch consistency of these inputs directly affect diagnostic reliability and regulatory acceptability.

Based on End User, diagnostic needs diverge across Diagnostic Laboratories, Government Agencies, Research Institutes, and Veterinary Hospitals. Diagnostic laboratories prioritize throughput, standardized quality control procedures, and regulatory compliance. Government agencies focus on surveillance integration, export-import implications, and outbreak response readiness. Research institutes emphasize assay development, validation, and epidemiological analytics, while veterinary hospitals require practical, rapid-result diagnostics that support clinical decision-making at the herd or individual animal level. Understanding these segment-specific priorities is essential to align product development, service models, and distribution strategies with real-world user constraints and expectations.

How distinct regional infrastructures, regulatory frameworks, and agricultural systems drive divergent diagnostic priorities and practical deployment strategies across global markets

Regional heterogeneity significantly shapes diagnostic adoption pathways, regulatory expectations, and supply chain architectures. In the Americas, well-established surveillance infrastructures and large commercial herds support routine deployment of both field screening tests and laboratory-based confirmatory assays. Laboratories in this region often prioritize high-throughput ELISA platforms and PCR confirmation for trace-back investigations, while also balancing the need for rapid point-of-care screening in remote production areas. Trade dynamics and cross-border disease management frameworks further incentivize harmonized diagnostic standards and collaborative surveillance initiatives.

Within Europe, Middle East & Africa, the diagnostic landscape is highly heterogeneous, encompassing regions with sophisticated laboratory networks alongside areas facing resource constraints. Regulatory harmonization efforts across parts of Europe provide a framework for standardized assay validation and mutual recognition, whereas in some Middle Eastern and African contexts, priorities include strengthening cold-chain logistics, local capacity building, and scalable, field-appropriate tests. Donor-supported programs and regional veterinary networks play a critical role in enabling access to diagnostics, while also creating opportunities for technology transfer and localized manufacturing to reduce dependency on long supply chains.

Asia-Pacific exhibits rapid modernization of diagnostic capabilities coupled with significant variation across national systems. Large-scale agricultural producers and research centers are investing in molecular confirmation and integrated data systems, yet smallholder-dominated regions emphasize low-cost, easy-to-use screening tests and decentralized sampling strategies. Cross-border trade, zoonotic risk awareness, and investments in laboratory accreditation are driving uptake of higher-sensitivity assays in some markets, while others adopt hybrid models that combine field screening with centralized confirmatory testing. Recognizing these regional contrasts is essential when designing distribution strategies, regulatory engagement plans, and capacity-building initiatives.

Commercial and technical strategies that define competitive advantage through assay quality, integrated support services, regulatory enablement, and resilient manufacturing footprints

Key company dynamics center on capabilities that span instrument innovation, kit formulation, reagent quality, and service delivery. Leading diagnostic firms and specialized manufacturers that invest in assay specificity, robust supply chains, and regulatory dossier development are better positioned to meet buyer expectations for validated, deployable solutions. Partnerships between instrument makers and reagent suppliers enhance compatibility and accelerate laboratory adoption through bundled offerings that simplify validation and reduce integration overhead.

Competitive differentiation increasingly relies on post-market support, training services, and digital enablement that streamline laboratory workflows. Companies offering laboratory information management integrations, remote calibration, and quality assurance programs add measurable value for large diagnostic networks and government programs. At the same time, upstream investments in assay research-particularly in antigen refinement and primer/probe design-are critical to maintaining clinical performance amid cross-reactivity challenges and evolving pathogen epidemiology.

Strategic moves such as regional manufacturing expansions, collaborations with academic groups for validation studies, and flexible commercial models that include reagent rental or reagent-as-a-service can materially influence market access. Firms that proactively address supply chain resilience, offer validated secondary sourcing, and provide clear regulatory support pathways for customers will be best placed to secure long-term institutional contracts and to support emergency response scenarios.

Practical and prioritized strategic interventions for diagnostic companies and institutional stakeholders to enhance validation, supply resilience, digital integration, and One Health collaboration

Industry leaders should prioritize a coordinated set of actions to strengthen diagnostic reliability, supply continuity, and market responsiveness. First, accelerating validation efforts across multiple matrices and host populations will reduce uncertainty when deploying assays in heterogeneous field conditions and facilitate regulatory acceptance. Investing in cross-laboratory proficiency testing and third-party validation studies builds confidence among procurement agencies and supports harmonized surveillance protocols.

Second, diversifying supply chains and expanding regional manufacturing or distribution hubs mitigates tariff and logistics risk while reducing lead times for critical instruments and reagents. Strategic partnerships with local manufacturers and contract development organizations can preserve product quality while improving responsiveness to sudden demand surges. Third, embedding digital connectivity into diagnostic workflows-through automated readers, cloud-based reporting, and interoperable LIMS-improves traceability, speed of reporting, and outbreak analytics, thereby delivering public health value beyond individual test results.

Fourth, companies should adopt flexible commercial models and invest in training programs for end users to enhance adoption and ensure correct test interpretation. Finally, alignment with One Health stakeholders through data-sharing initiatives and joint training fosters integrated responses to zoonotic risk and elevates the role of diagnostic evidence in policy-making and trade negotiations. Executing these recommendations will strengthen operational readiness and create competitive differentiation in a dynamic diagnostic environment.

A transparent and reproducible mixed-methods research approach that integrates technical literature, primary stakeholder interviews, and laboratory observations to validate diagnostic insights

The research underpinning this analysis combined structured reviews of peer-reviewed publications, regulatory guidance documents, and technical standards with primary qualitative interviews and facility-level observations. Secondary literature provided context on assay performance characteristics, regulatory pathways, and historical surveillance protocols, while an array of expert interviews with laboratory directors, veterinarians, and procurement specialists offered operational perspectives on adoption barriers and real-world workflows.

Primary data collection included semi-structured interviews to explore validation requirements, supply chain experiences, and post-market support expectations. Field observations in diagnostic laboratories and veterinary clinics informed assessments of throughput constraints, cold-chain practices, and staff training needs. Triangulation across these inputs ensured that conclusions reflect both technical performance metrics and practical operational realities. Quality control measures included independent review of technical summaries by subject-matter experts and cross-validation of key findings against public regulatory guidance and published assay evaluations.

The methodology emphasized transparency and reproducibility by documenting data sources, interview guides, and validation steps. Stakeholder engagement prioritized representativeness across laboratory types and geographical regions to capture heterogeneity in needs and capabilities. Where applicable, sensitivity checks and scenario analyses were used to test the robustness of recommendations under different operational and trade conditions.

A concise synthesis highlighting the imperative for interoperable, validated, and resilient diagnostic systems that support surveillance, trade, and public health objectives

Effective management of bovine tuberculosis diagnostics requires an integrated perspective that aligns technological capabilities with operational constraints and policy objectives. Diagnostic selection is not a purely technical choice; it intersects with regulatory frameworks, trade considerations, and the capacity of end users to implement and sustain testing workflows. The combined effect of evolving assay technologies, shifting procurement landscapes, and regional heterogeneity underscores the need for adaptive strategies that prioritize validation, resilience, and interoperability.

Decision-makers should focus on building modular diagnostic ecosystems where screening, confirmation, and data management components are interoperable and supported by clear validation evidence and supply chain contingencies. Cross-sector collaboration and investment in local capacity can reduce vulnerabilities and enable faster, evidence-based responses to outbreaks. Ultimately, strengthening diagnostic systems for bovine tuberculosis yields benefits that extend into public health, trade confidence, and animal productivity, making it a high-priority area for coordinated investment and policy attention.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of CRISPR-Cas12a lateral flow assays for ultrasensitive on-farm btb antigen detection in high-density cattle herds
  • 5.2. Integration of smartphone-enabled infrared thermographic imaging with machine learning models for early subclinical bovine tb screening in dairy operations
  • 5.3. Development of multiplexed microfluidic lab-on-a-chip platforms for simultaneous detection of bovine tuberculosis and other respiratory pathogens at point of need
  • 5.4. Implementation of portable real-time PCR diagnostics with lyophilized reagents for rapid confirmation of bovine tb in remote livestock trading hubs
  • 5.5. Deployment of nanobody-functionalized electrochemical biosensors to enhance specificity and sensitivity in bovine tb antibody surveillance programs
  • 5.6. Regulatory approval trends for novel interferon-gamma release assays and their impact on national bovine tuberculosis eradication strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bovine Tuberculosis Diagnosis Market, by Test Type

  • 8.1. Caudal Fold Test
    • 8.1.1. Comparative Intradermal Cervical Test
    • 8.1.2. Single Intradermal Cervical Test
  • 8.2. Elisa
  • 8.3. Gamma Interferon Assay
  • 8.4. PCR

9. Bovine Tuberculosis Diagnosis Market, by Product

  • 9.1. Instruments
    • 9.1.1. Elisa Readers
    • 9.1.2. Pcr Machines
  • 9.2. Kits
    • 9.2.1. Caudal Fold Test Kits
    • 9.2.2. Elisa Kits
    • 9.2.3. Gamma Interferon Assay Kits
    • 9.2.4. PCR Kits
  • 9.3. Reagents
    • 9.3.1. Antigens
    • 9.3.2. Enzymes
    • 9.3.3. Primers And Probes
      • 9.3.3.1. Primers
      • 9.3.3.2. Probes

10. Bovine Tuberculosis Diagnosis Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Government Agencies
  • 10.3. Research Institutes
  • 10.4. Veterinary Hospitals

11. Bovine Tuberculosis Diagnosis Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Bovine Tuberculosis Diagnosis Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Bovine Tuberculosis Diagnosis Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Thermo Fisher Scientific Inc.
    • 14.3.2. Zoetis Inc.
    • 14.3.3. IDEXX Laboratories, Inc.
    • 14.3.4. Bio-Rad Laboratories, Inc.
    • 14.3.5. Merck & Co., Inc.
    • 14.3.6. Neogen Corporation
    • 14.3.7. HIPRA S.A.
    • 14.3.8. Elanco Animal Health Incorporated
    • 14.3.9. Biogal-Galed Laboratories Ltd.
    • 14.3.10. VMRD, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BOVINE TUBERCULOSIS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. BOVINE TUBERCULOSIS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BOVINE TUBERCULOSIS DIAGNOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COMPARATIVE INTRADERMAL CERVICAL TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COMPARATIVE INTRADERMAL CERVICAL TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COMPARATIVE INTRADERMAL CERVICAL TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COMPARATIVE INTRADERMAL CERVICAL TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COMPARATIVE INTRADERMAL CERVICAL TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COMPARATIVE INTRADERMAL CERVICAL TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SINGLE INTRADERMAL CERVICAL TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SINGLE INTRADERMAL CERVICAL TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SINGLE INTRADERMAL CERVICAL TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SINGLE INTRADERMAL CERVICAL TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SINGLE INTRADERMAL CERVICAL TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SINGLE INTRADERMAL CERVICAL TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA READERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA READERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA READERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA READERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA READERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA READERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR MACHINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR MACHINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR MACHINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ANTIGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ANTIGENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ANTIGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ANTIGENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ANTIGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ANTIGENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PROBES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PROBES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PROBES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PROBES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PROBES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PROBES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GOVERNMENT AGENCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GOVERNMENT AGENCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GOVERNMENT AGENCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GOVERNMENT AGENCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)

TAB